Literature DB >> 9046950

Hypertension in pregnancy: current concepts of preeclampsia.

A G Witlin1, B M Sibai.   

Abstract

Hypertensive disorders (gestational hypertension, preeclampsia, chronic hypertension, superimposed preeclampsia) are the most common medical complications of pregnancy and constitute a major cause of maternal and perinatal morbidity and mortality. Prediction of those women destined to develop preeclampsia remains elusive. The benefits of calcium supplementation for prevention of preeclampsia are encouraging; however, the definitive study is not yet complete. Aspirin therapy for high-risk has not been helpful; results of therapy for high-risk women are pending. More experience is being gained with antihypertensive therapy and expectant management in severe preeclampsia. Conservative management of severe preeclampsia, when performed in a tertiary care center, may benefit a select group of women and their fetuses.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9046950     DOI: 10.1146/annurev.med.48.1.115

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  15 in total

1.  Prenatal health, educational attainment, and intergenerational inequality: the Northern Finland Birth Cohort 1966 Study.

Authors:  Juho Härkönen; Hande Kaymakçalan; Pirjo Mäki; Anja Taanila
Journal:  Demography       Date:  2012-05

2.  Birth weight and ponderal index in pre-eclampsia: a comparative study.

Authors:  Sa Obed; Aniteye Patience
Journal:  Ghana Med J       Date:  2006-03

3.  Fetal growth restriction alters transcription factor binding and epigenetic mechanisms of renal 11beta-hydroxysteroid dehydrogenase type 2 in a sex-specific manner.

Authors:  Mariana Baserga; Rajwinderjit Kaur; Merica A Hale; Allyson Bares; Xing Yu; Christopher W Callaway; Robert A McKnight; Robert H Lane
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-04-28       Impact factor: 3.619

4.  Partial correlation network analyses to detect altered gene interactions in human disease: using preeclampsia as a model.

Authors:  Asa Johansson; Mari Løset; Siv B Mundal; Matthew P Johnson; Katy A Freed; Mona H Fenstad; Eric K Moses; Rigmor Austgulen; John Blangero
Journal:  Hum Genet       Date:  2010-10-08       Impact factor: 4.132

5.  Uteroplacental insufficiency affects kidney VEGF expression in a model of IUGR with compensatory glomerular hypertrophy and hypertension.

Authors:  Mariana Baserga; Allyson L Bares; Merica A Hale; Christopher W Callaway; Robert A McKnight; Pascale H Lane; Robert H Lane
Journal:  Early Hum Dev       Date:  2009-02-01       Impact factor: 2.079

Review 6.  Impact of direct soil exposures from airborne dust and geophagy on human health.

Authors:  David Sing; Charles F Sing
Journal:  Int J Environ Res Public Health       Date:  2010-03-19       Impact factor: 3.390

7.  Genetic association of the activin A receptor gene (ACVR2A) and pre-eclampsia.

Authors:  E Fitzpatrick; M P Johnson; T D Dyer; S Forrest; K Elliott; J Blangero; S P Brennecke; E K Moses
Journal:  Mol Hum Reprod       Date:  2009-01-06       Impact factor: 4.025

8.  Epigenetics: intrauterine growth retardation (IUGR) modifies the histone code along the rat hepatic IGF-1 gene.

Authors:  Qi Fu; Xing Yu; Christopher W Callaway; Robert H Lane; Robert A McKnight
Journal:  FASEB J       Date:  2009-04-13       Impact factor: 5.191

9.  A genome scan in families from Australia and New Zealand confirms the presence of a maternal susceptibility locus for pre-eclampsia, on chromosome 2.

Authors:  E K Moses; J A Lade; G Guo; A N Wilton; M Grehan; K Freed; A Borg; J D Terwilliger; R North; D W Cooper; S P Brennecke
Journal:  Am J Hum Genet       Date:  2000-10-17       Impact factor: 11.043

10.  Relationship of circulating cell-free DNA levels to cell-free fetal DNA levels, clinical characteristics and laboratory parameters in preeclampsia.

Authors:  Levente Lazar; János Rigó; Bálint Nagy; Krisztián Balogh; Veronika Makó; László Cervenak; Miklós Mézes; Zoltán Prohászka; Attila Molvarec
Journal:  BMC Med Genet       Date:  2009-11-21       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.